β‐catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β‐catenin and MET

Yan Liang, Yun Feng, Min Zong, Xu‐Fu Wei, Jin Lee, Yukuan Feng, Hairi Li, Guang‐Shun Yang, Zhong‐Jun Wu, Xiang‐Dong Fu, Gen‐Sheng Feng – 20 November 2017 – Both activating and inactivating mutations in catenin β1 (ctnnb1), which encodes β‐catenin, have been implicated in liver tumorigenesis in humans and mice, although the underlying mechanisms are not fully understood.

Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness

Shan Wan, Anne‐Sophie Meyer, Sofia Maria Elisabeth Weiler, Christian Rupp, Marcell Tóth, Carsten Sticht, Stephan Singer, Stefan Thomann, Stephanie Roessler, Marina Schorpp‐Kistner, Jennifer Schmitt, Norbert Gretz, Peter Angel, Darjus Felix Tschaharganeh, Jens Marquardt, Peter Schirmacher, Federico Pinna, Kai Breuhahn – 20 November 2017 – The loss of epithelial cell polarity plays an important role in the development and progression of liver cancer. However, the specific molecular mechanisms supporting tumor initiation and progression are poorly understood.

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Zobair M. Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R. Lenderking, Anne Skalicky, Leah Kleinman, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Cynthia Levy, Christopher L. Bowlus, Kris Kowdley, Andrew J. Muir – 20 November 2017 – Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC‐specific patient‐reported outcome (PRO) instrument.

New insights into diagnosis and therapeutic options for proliferative hepatoblastoma

Katarzyna B. Hooks, Jérôme Audoux, Helena Fazli, Sarah Lesjean, Tony Ernault, Nathalie Dugot‐Senant, Thierry Leste‐Lasserre, Martin Hagedorn, Benoit Rousseau, Coralie Danet, Sophie Branchereau, Laurence Brugières, Sophie Taque, Catherine Guettier, Monique Fabre, Anne Rullier, Marie‐Annick Buendia, Thérèse Commes, Christophe F. Grosset, Anne‐Aurélie Raymond – 20 November 2017 – Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70%‐80% of patients.

Subscribe to